Clients in the media Clients IN the MEDIA

Ensuring your story is visible.

AI And Machine Learning Help Unravel The Biology Of Alzheimer’s

Alkahest is a clinical stage company with multiple therapeutic candidates in Phase 2 trials. The company is hoping to develop a treatment for patients with Alzheimer’s but is taking a different path. Alkahest is looking at the plasma proteome and, specifically, how it changes with age.

‘Smart’ Inhaler Can Make Insulin Delivery Quick and Painless

One of the main barriers to medication adherence among diabetics is the painful, constant administration of insulin using a needle and syringes. Moreover, subcutaneous insulin administration has long been admonished for its slow onset of action. People living with this chronic condition need a convenient and efficient method of administering this crucial hormone. Biopharmaceutical company Aerami Therapeutics (formerly Dance Biopharm) may have a solution that changes the way insulin is delivered.

Spring resident finds hope in new migraine treatment device

Spring resident Leah Cravens wanted to have a baby. With her husband diagnosed with cystic fibrosis, rendering him infertile, an in vitro fertilization was her only choice. The problem? Chronic migraines have been plaguing Cravens for more than 20 years, the medicine for which would be unsafe during her pregnancy.

Lyme Vaccines Show New Promise, and Face Old Challenges

Jessica Reeder worries about ticks and the diseases they carry. She had Lyme disease, her brother had Lyme disease, and every fall her children come home from school with notes reminding parents to do a nightly tick check. Even in Philadelphia, where Reeder lives, the bloodsuckers lurk in the woods around the playground. Her family used to go tent camping with friends, but they stopped after a few people in the group contracted Lyme.

td ameritrade

Marc Schegerin, chief financial officer of ArQule, on its breakout year and its MOSAIC trial

Marc Schegerin, chief financial officer of ArQule, discusses ArQule’s breakout year including data showing clinical efficacy of ARQ 531 in CLL and the initiation of its MOSAIC trial

SanFranBusTimes

Drug company’s Bay Area exodus: All about a new CEO, the right talent — and getting out of founder’s living room

Dance BioPharma has joined the Bay Area exodus, but its story is unlike some of the more high-profile departures.

TCT 2019 – Orchestra data could lead to a duet

Data on the company’s pacemaker-neurostimulator combo are probably good enough to permit further development – but first the company wants to hook a partner.

Could Aiming Insulin at the Liver Be an Answer to Using Less?

Amid the debate about why insulin costs so much lies a second question: if the hormone can be delivered more efficiently, will people with diabetes need less insulin? It’s not just a question that’s come up in the era of the artificial pancreas, as people with type 1 diabetes (T1D) work with technology that uses an algorithm to anticipate their blood glucose levels and make constant adjustments to their insulin needs. A company called Diasome is pushing the idea further, by trying to take insulin to the place where it would go if created by islet cells and released by a human pancreas: straight to the liver.